Somaxon Pharmaceuticals — Technical Presentation (June 2008)
21 slides from Somaxon Pharmaceuticals's technical presentation, Jun 12, 2008
Slide 1: Long-term Efficacy and Safety of Doxepin 1 mg and 3 mg in Elderly Subjects with Chronic Primary Insomnia
Long-term Efficacy and Safety of Doxepin 1 mg and 3 mg in Elderly Subjects with Chronic Primary Insomnia Thomas Roth, PhD, Mark Gotfried, MD, Steven Hull, MD, Bruce Corser, MD, Martin Scharf, PhD, William Orr, MD, Venkata Buddharaju, MD, Howard Schwartz, MD, Philip Jochelson, MD, Elizabeth Ludington
Slide 2: Introduction
Introduction Insomnia is more prevalent and severe in elderly Increased rates of sleep maintenance impairment and early morning awakenings Elderly insomnia patients often take sedative- hypnotics for extended periods of time Sometimes longer than clinically evaluated and recommended Underscores need
Slide 3: Mechanism of Action
Mechanism of Action Sleep promoting effects of doxepin (DXP) likely mediated through histaminergic system DXP at doses of 1 mg, 3 mg, and 6 mg is a highly potent and selective histamine receptor antagonist This selectivity is dose-dependent Histamine is an important mediator of wakefulness in sleep-
Slide 4: Study Design
Study Design Study objectives Efficacy and safety of DXP 1 mg and 3 mg in a long-term trial (12 weeks) of elderly subjects with primary insomnia Potential for tolerance and next-day residual effects Randomized, DB, placebo-controlled, parallel-group Key eligibility criteria ^65 years of age with his
Slide 5: Study Design Schematic
Study Design Schematic Visit may oscur at any wee Final Study this period pal Si Visit yas ig Wisi Visit Visita Visits Visits Visit? Visite N8,NS5 Nt N15 N29 N57 N85 086 a PSG Screen & Iniaseenng faseotansn © Patho a . re a id so 0 > N= Night D = Day V_ PSG Assessment © Randomization Note: At Day 0
Slide 6: Data Analyses
Data Analyses Efficacy analyses performed on ITT data set (N=240) Subset of subjects had IVRS data (n=191) ANCOVA used to compare WASO from N1 (primary endpoint) between PBO, DXP 1 mg, or DXP 3 mg Same methods applied to other continuous efficacy variables Scores on CGI-Improvement and PGI assessed
Slide 7: Disposition
Disposition (Overall N=240) Placebo (N=81) DXP 1 mg (N=77) DXP 3 mg (N=82) Completed Study 70 (86%) 70 (91%) 74 (90%) Discontinued from Study 11 (14%) 7 (9%) 8 (10%) Adverse Event 3 (4%) 1 (1%) 2 (2%) Protocol Violation 2 (2%) 2 (3%) 1 (1%) Non-compliance 0 (0%) 3 (4%) 0 (0%) Consent Withdrawn 6 (7%
Slide 8: WASO at Baseline, Night 1 and Night 85
WASO at Baseline, Night 1 and Night 85 Minutes (mean) <0.0001 <0.0001 0.0053 0.0330 p-value 1 mg 3 mg Baseline Night 1 Night 85 PBO 119.5 108.9 109.2 DXP 1 mg 120.1 91.8 97 DXP 3 mg 117.9 74.5 75.7 DXP 3 mg DXP 1 mg PBO
Slide 9: sTST at Baseline, Week 1 and Week 12 (IVRS)
sTST at Baseline, Week 1 and Week 12 (IVRS) Minutes (mean) Baseline Week 1 Week 12 PBO 280.2 316.2 326 DXP 1 mg 297.6 319.7 372 DXP 3 mg 308.7 357 389.4 0.0043 0.0001 0.9066 0.0027 p-value 1 mg 3 mg DXP 3 mg DXP 1 mg PBO
Slide 10: LSO at Baseline, Week 1 and Week 12 (IVRS)
LSO at Baseline, Week 1 and Week 12 (IVRS) Minutes (mean) Baseline Week 1 Week 12 PBO 56.3 59.7 55.5 DXP 1 mg 60.8 54.2 37.5 DXP 3 mg 48 40 39.9 DXP 3 mg DXP 1 mg PBO 0.0033 0.0464 0.2420 0.0028 p-value 1 mg 3 mg
Slide 11: Other PSG Data at Night 1
Parameter Placebo Doxepin 1 mg Doxepin 3 mg LPS Mean (SD) 39.6 (29.3) 38.8 (29.6) 28.6 (20.5) TST Mean (SD) 339.7 (54.4) 359.1* (53.1) 382.9^ (44.2) WTAS Mean (SD) 10.7 (22.6) 8.9 (18.8) 4.7 (14.6) Other PSG Data at Night 1 * p<0.05, vs PBO; ^ p=0.0007 vs PBO
Slide 12: Efficacy Throughout the Night: Sleep Efficiency % by Hour on Night 1
Efficacy Throughout the Night: Sleep Efficiency % by Hour on Night 1 p-value 1 mg 3 mg 0.0028 0.0024 0.0211 <0.0001 DXP 1 mg DXP 3 mg PBO 0.8579 0.0166 0.8732 0.1972 0.6953 0.0566 0.0322 0.0127 0.2162 0.0086 0.3343 0.0165 PBO DXP 1mg DXP 3mg 0 1 0.509 0.519 0.613 2 0.794 0.788 0.836 3 0.815 0.793 0.
Slide 13: Efficacy on Early Morning Awakenings: Sleep Efficiency % by Hour on Night 1
Efficacy on Early Morning Awakenings: Sleep Efficiency % by Hour on Night 1 p-value 1 mg 3 mg 0.0028 0.0024 0.0211 <0.0001 DXP 1 mg DXP 3 mg PBO 0.8579 0.0166 0.8732 0.1972 0.6953 0.0566 0.0322 0.0127 0.2162 0.0086 0.3343 0.0165 PBO DXP 1mg DXP 3mg 0 1 0.509 0.519 0.613 2 0.794 0.788 0.836 3 0.815 0
Slide 14: Next-day Residual Effects on Night 1
Score DSST SCT VAS PBO 48 94 59 DXP 1 mg 49 95 59 DXP 3 mg 47 89 62 Next-day Residual Effects on Night 1 Note: Plotting of VAS is inverted for consistency with DSST and SCT results DXP 1 mg DXP 3 mg PBO No Significant Effects on any Parameter
Slide 15: Next-day Residual Effects on Night 85
Score DSST SCT VAS PBO 50 92 56 DXP 1 mg 51 97 64 DXP 3 mg 47 90 61 Next-day Residual Effects on Night 85 Note: Plotting of VAS is inverted for consistency with DSST and SCT results DXP 1 mg DXP 3 mg PBO No Significant Effects on any Parameter
Slide 16: CGI-Severity at Baseline, After 2 Weeks and After 12 Weeks
CGI-Severity at Baseline, After 2 Weeks and After 12 Weeks 0.0005 0.0101 CGI-Severity Rating p-value 1 mg 3 mg 0.0047 0.7383 Marked Mild Moderate PBO DXP 1mg DXP 3mg Baseline 4.3 4.4 4.2 Week 2 4 4.1 3.5 Week 12 3.8 3.4 3.1 Note: Severity categories are Normal, Very Mild, Mild, Moderate, Marked, Sev
Slide 17: PGI Items After 12 Weeks
% of Subjects Reporting Yes Helped Sleep Shortened Onset Increased Duration Got Better Sleep Drug Strength Just Right PBO 0.41 0.37 0.36 0.4 0.29 DXP 1 mg 0.72 0.55 0.58 0.67 0.51 DXP 3 mg 0.74 0.64 0.68 0.74 0.54 * * * * * * * * * * DXP 3 mg DXP 1 mg PBO PGI Items After 12 Weeks * p<0.05, vs PBO
Slide 18: Adverse Events
Adverse Event Placebo (N=81) DXP 1 mg (N=77) DXP 3 mg (N=82) OVERALL 52% 40% 38% Headache 14% 3% 6% Somnolence/Sedation 5% 5% 3% Diarrhea 2% 3% 0% Upper Respiratory Tract Infection 1% 3% 1% Sinusitis 1% 4% 0% Hypertension 0% 1% 4% Gastroenteritis 0% 0% 4% Adverse Events Note: Adverse events listed a
Slide 19: Sleep Architecture on Night 1
Sleep Architecture on Night 1 * Stg 3/4 Stg 2 Stg 1 REM * Minutes (mean) * p<0.05, versus placebo PBO DXP 1 mg DXP 3 mg REM Sleep 61 61 61 Stage 3/4 Sleep 33 35 42 Stage 2 Sleep 199 214 234 Stage 1 Sleep 48 49 46 * * * TST=340 TST=359 TST=383 * *
Slide 20: Study Summary
Produced significant sleep improvements that were sustained after 12 weeks for most parameters Improvements in sleep onset, maintenance and early morning awakenings Demonstrated improvements in patient- and physician- based ratings of global insomnia outcomes Nearly full category improvement vs PBO
Slide 21: Conclusion
Trial represents longest PBO-controlled, DB, PSG trial in elderly with primary insomnia Improvements in PSG, patient reports, and global outcomes measures DXP 1 mg and 3 mg well-tolerated Proposed selective histaminergic MOA supported by: Improvements in early morning awakenings without significant
Somaxon Pharmaceuticals — Technical Presentation (June 2008) on 6ix